PL2391363T3 - Kompozycje i sposoby do leczenia raka - Google Patents

Kompozycje i sposoby do leczenia raka

Info

Publication number
PL2391363T3
PL2391363T3 PL10736502T PL10736502T PL2391363T3 PL 2391363 T3 PL2391363 T3 PL 2391363T3 PL 10736502 T PL10736502 T PL 10736502T PL 10736502 T PL10736502 T PL 10736502T PL 2391363 T3 PL2391363 T3 PL 2391363T3
Authority
PL
Poland
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
PL10736502T
Other languages
English (en)
Inventor
Young Hee Ko
Original Assignee
Young Hee Ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Young Hee Ko filed Critical Young Hee Ko
Publication of PL2391363T3 publication Critical patent/PL2391363T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL10736502T 2009-01-29 2010-01-29 Kompozycje i sposoby do leczenia raka PL2391363T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14838509P 2009-01-29 2009-01-29

Publications (1)

Publication Number Publication Date
PL2391363T3 true PL2391363T3 (pl) 2017-03-31

Family

ID=42396378

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10736502T PL2391363T3 (pl) 2009-01-29 2010-01-29 Kompozycje i sposoby do leczenia raka

Country Status (17)

Country Link
US (1) US8022042B2 (pl)
EP (1) EP2391363B1 (pl)
JP (2) JP6068803B2 (pl)
KR (1) KR20110110355A (pl)
CN (1) CN102387801A (pl)
AU (1) AU2010208062B2 (pl)
CA (2) CA2750944C (pl)
DK (1) DK2391363T3 (pl)
ES (1) ES2607211T3 (pl)
HR (1) HRP20161686T1 (pl)
HU (1) HUE032389T2 (pl)
IL (1) IL214349A (pl)
NZ (1) NZ594434A (pl)
PL (1) PL2391363T3 (pl)
PT (1) PT2391363T (pl)
SI (1) SI2391363T1 (pl)
WO (1) WO2010088564A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324175B2 (en) * 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
EP2932994B1 (en) 2009-07-30 2017-11-08 Tandem Diabetes Care, Inc. New o-ring seal, and delivery mechanism and portable infusion pump system related thereto
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
CN103610671A (zh) * 2013-12-10 2014-03-05 江苏长泰药业有限公司 丙酮酸药物组成及其在制备治疗肺癌药物中的用途
EP3293167A1 (en) 2016-09-09 2018-03-14 Université Catholique De Louvain [18f]-labelled lactate derivative as pet radiotracer
US10245235B2 (en) 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
CA3056086A1 (en) * 2017-03-15 2018-09-20 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2023196543A2 (en) * 2022-04-06 2023-10-12 Young Hee Ko Liquid-dispersible halopyruvate formulations and associated methods
CN116375769A (zh) * 2023-03-10 2023-07-04 云南贵金属实验室有限公司 一种双靶点Pt(IV)抗癌前药及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086627B1 (en) 1982-02-12 1985-08-28 Unitika Ltd. Anti-cancer device
US5800820A (en) 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5284786A (en) * 1992-08-14 1994-02-08 National Semiconductor Corporation Method of making a split floating gate EEPROM cell
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6284786B1 (en) 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6448030B1 (en) 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US20020068711A1 (en) 2000-03-14 2002-06-06 Pedersen Peter L. Arrest of proliferation of highly glycolytic tumors
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
AU2002233916A1 (en) 2000-08-03 2002-04-29 Albert Einstein College Of Medicine Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection
US7381713B2 (en) 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
US7547673B2 (en) 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
WO2004013307A2 (en) 2002-08-05 2004-02-12 Mirus Corporation Compounds for targeting hepatocytes
CA2498130A1 (en) 2002-09-05 2004-03-18 Invitrogen Corporation Compositions and methods for synthesizing nucleic acids
US20040229826A1 (en) * 2002-12-12 2004-11-18 Larry Norton Dose-dense & sequential adjuvant cancer chemotherapy
CA2513399A1 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US20060172953A1 (en) * 2003-01-17 2006-08-03 Threshold Pharmaceuticals Inc. Treatment of benign prostatic hyperplasia using energolytic agents
CA2513575A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
AU2005274165A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
JP2008540566A (ja) * 2005-05-12 2008-11-20 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド ２−デオキシグルコースを用いたがんの処置
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
EP2114413B1 (en) * 2006-12-18 2014-10-22 The Johns Hopkins University Therapeutics for treating cancer using 3-bromopyruvate

Also Published As

Publication number Publication date
CA2750944C (en) 2019-01-08
PT2391363T (pt) 2016-12-23
JP6068803B2 (ja) 2017-01-25
AU2010208062A1 (en) 2011-08-18
US8022042B2 (en) 2011-09-20
IL214349A0 (en) 2011-09-27
DK2391363T3 (en) 2017-01-16
SI2391363T1 (sl) 2017-01-31
US20100197612A1 (en) 2010-08-05
JP2012516358A (ja) 2012-07-19
EP2391363A2 (en) 2011-12-07
KR20110110355A (ko) 2011-10-06
CA3024263A1 (en) 2010-08-05
IL214349A (en) 2015-02-26
AU2010208062B2 (en) 2014-07-24
EP2391363B1 (en) 2016-09-28
EP2391363A4 (en) 2012-09-19
ES2607211T3 (es) 2017-03-29
WO2010088564A2 (en) 2010-08-05
CA2750944A1 (en) 2010-08-05
HRP20161686T1 (hr) 2017-02-24
JP2015180680A (ja) 2015-10-15
CN102387801A (zh) 2012-03-21
NZ594434A (en) 2014-11-28
WO2010088564A3 (en) 2010-12-29
HUE032389T2 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
IL258794B (en) Methods and preparations for the diagnosis and treatment of cancer
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
HK1159498A1 (en) Methods and compositions for the treatment of cancer
IL218987A0 (en) Methods and compositions for treating cancer
IL251083B (en) Compounds and preparations for the treatment of cancer
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL214349A0 (en) Compositions and methods for the treatment of cancer
HK1166305A1 (zh) 用於治療炎症的組合物及方法
EP2480687A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF THYROID CANCER
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP2635273A4 (en) ISOFLAVONOID COMPOSITIONS AND METHOD FOR CANCER TREATMENT
EP2411031A4 (en) Methods and compositions for the treatment of cancer
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT